Evidence map›Paper›PMID 35766272›Full record

ArticleJournal of the American Heart Association2022

B-Type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart Disease.

Ralph A H Stewart, Adrienne Kirby, Harvey D White, Simone L Marschner, Malcolm West, Peter L Thompson, David Sullivan, Edward Janus, David Hunt, Leonard Kritharides and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Predictive Value of SAPS II for 28-Day All-Cause Mortality in AECOPD Patients Admitted to the ICU.International journal of chronic obstructive pulmonary disease · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Ralph A H StewartGreen Lane Cardiovascular Service Auckland City Hospital Auckland New Zealand.ORCID 0000-0002-6167-1225
Adrienne KirbyNational Health and Medical Research Council Clinical Trials Centre University of Sydney Camperdown Australia.ORCID 0000-0003-2662-4471
Harvey D WhiteGreen Lane Cardiovascular Service Auckland City Hospital Auckland New Zealand.ORCID 0000-0001-7712-6750
Simone L MarschnerNational Health and Medical Research Council Clinical Trials Centre University of Sydney Camperdown Australia.ORCID 0000-0002-5484-9144
Malcolm WestDepartment of Medicine University of Queensland Brisbane Australia.
Peter L ThompsonSchool of Population Health University of Western Australia Perth Australia.
David SullivanDepartment of Clinical Biochemistry Royal Prince Alfred Hospital Sydney Australia.ORCID 0000-0003-3085-5627
Edward JanusWestern Health Chronic Disease Alliance and Department of Medicine, Western Health - Melbourne Medical School The University of Melbourne Melbourne Australia.ORCID 0000-0002-0023-5710
David HuntDepartment of Medicine University of Melbourne Melbourne Australia.
Leonard KritharidesConcord Repatriation General Hospital University of Sydney Sydney Australia.ORCID 0000-0001-5818-8024
Anthony KeechNational Health and Medical Research Council Clinical Trials Centre University of Sydney Camperdown Australia.
John SimesNational Health and Medical Research Council Clinical Trials Centre University of Sydney Camperdown Australia.
Andrew M TonkinSchool of Public Health and Preventive Medicine Monash University Melbourne Australia.ORCID 0000-0001-5291-0610
The University of Sydney · AUAuckland City Hospital · NZThe University of Melbourne · AUMonash University · AURoyal Prince Alfred Hospital · AUThe University of Queensland · AUThe University of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The plasma concentration of B-type natriuretic peptide (BNP) is a strong predictor of adverse cardiovascular events. The aim of this study was to determine whether the association between plasma BNP concentration and cardiovascular mortality is sustained or diminishes with increasing time after BNP is measured. Methods and Results Six thousand seven hundred forty patients with a history of myocardial infarction or unstable angina who participated in the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) trial had plasma BNP concentration measured at baseline and after 1 year. Associations with cardiovascular mortality were evaluated in landmark analyses 1 to <5, 5 to <10, and 10 to 16 years after randomization. There were 1640 cardiovascular deaths. The cardiovascular mortality rate increased progressively from 10.2 to 19.1 to 26.3/1000 patient-years from 1 to <5, 5 to <10, and 10 to 16 years after baseline, respectively. The average of baseline and 1-year BNP concentration was more strongly associated with cardiovascular mortality compared with baseline or 1-year BNP only. The hazard ratio (HR) for cardiovascular death associated with each doubling of average BNP concentration was similar during years 1 to <5 (HR, 1.53 [95% CI, 1.44-1.63]), years 5 to <10 (HR, 1.52 [95% CI, 1.44-1.60]), and years 10-16 (HR, 1.43 [95% CI, 1.36-1.50]),

Indexed as

Coronary DiseaseMyocardial InfarctionBiomarkersHumansNatriuretic Peptide, BrainPredictive Value of TestsPrognosisRisk FactorsBiomarkersNatriuretic Peptide, Braincardiac biomarkersrisk prediction

Identifiers

PMID35766272
PMCPMC9333402
OpenAlexW4283693802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.